200 300 400 500 600 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg The APEX study is ongoing. Final results may be different due to additional data collection or data cleaning. Includes patients in the per protocol set that completed the Week 12 visit and met all the eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). 54 Meaningful anatomical improvements are rapidly achieved, with OCT CST levels <325 μm observed as early as Week 4, further deepening over time Mean CST (μm) Observed OCT CST over time Weeks Dose Level Dryness (CST 250-325) 2.5 mg 13 12 13 13 13 13 13 5 mg 13 13 13 13 13 13 13 10 mg 13 13 13 13 13 12 12 Sample Size Mean Change -218 -230 -151 Preliminary Analysis New Data